# Clinical Outcome and Cost-effectiveness of Reduced Noradrenaline by Using a Lower Blood Pressure Target in Patients With Cardiogenic Shock From Acute Myocardial Infarction

Study · id `cardio:ct-nct05168462` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05168462](<https://clinicaltrials.gov/study/NCT05168462>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05168462

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease; Acute care and long-term living  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 776 participants.

## Technical summary

Registry record NCT05168462. Randomized; no masking; primary purpose treatment. Start 2022-10-01 (actual); primary completion 2027-04-01 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 776 participants (planned count; ClinicalTrials.gov record NCT05168462, source copy `cardio:ctgov-nct05168462-2026-03-27`, retrieved 2026-10-26)
- Started: 2022-10-01 (actual) (ClinicalTrials.gov record NCT05168462, source copy `cardio:ctgov-nct05168462-2026-03-27`, retrieved 2026-10-26)
- Primary completion: 2027-04-01 (anticipated) (ClinicalTrials.gov record NCT05168462, source copy `cardio:ctgov-nct05168462-2026-03-27`, retrieved 2026-10-26)
- Completion: 2028-04-01 (anticipated) (ClinicalTrials.gov record NCT05168462, source copy `cardio:ctgov-nct05168462-2026-03-27`, retrieved 2026-10-26)
- Countries: Netherlands (ClinicalTrials.gov record NCT05168462, source copy `cardio:ctgov-nct05168462-2026-03-27`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05168462-2026-03-27`, retrieved 2026-10-26)

## The registry's words

- Brief title: Clinical Outcome and Cost-effectiveness of Reduced Noradrenaline by Using a Lower Blood Pressure Target in Patients With Cardiogenic Shock From Acute Myocardial Infarction
- Acronym: NORSHOCK
- Condition: Cardiogenic Shock
- Condition: Myocardial Infarction
- Intervention (Drug): Reduced noradrenaline use
- Lead sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Cardiogenic shock (`cardio:cardiogenic-shock`)
- Registry condition terms include this condition: Heart attack (myocardial infarction) (`cardio:myocardial-infarction`)
- Registry lists this organization as the lead sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) (`cardio:org-academisch-medisch-centrum-universiteit-van-amsterdam-amc-662d32`)

## Provenance

Content hash: fc977ddbc8cf9af5c4f7203db2ea525bc5d76aafac329c8eb4e11ff55f70342b
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
